1. Home
  2. HWBK vs TRDA Comparison

HWBK vs TRDA Comparison

Compare HWBK & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HWBK

Hawthorn Bancshares Inc.

HOLD

Current Price

$39.43

Market Cap

253.0M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.69

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWBK
TRDA
Founded
1865
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.0M
274.5M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
HWBK
TRDA
Price
$39.43
$7.69
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
12.6K
281.2K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
2.49%
N/A
EPS Growth
31.42
N/A
EPS
0.83
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
$48.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.10
$4.93
52 Week High
$40.36
$16.45

Technical Indicators

Market Signals
Indicator
HWBK
TRDA
Relative Strength Index (RSI) 55.17 53.59
Support Level $33.50 $5.75
Resistance Level N/A $10.82
Average True Range (ATR) 1.56 0.50
MACD 0.06 0.22
Stochastic Oscillator 68.61 78.53

Price Performance

Historical Comparison
HWBK
TRDA

About HWBK Hawthorn Bancshares Inc.

Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, and checking, savings and money market accounts. It has two segments, banking and wealth management, with the banking segment earning the majority of its revenue and conducting general banking business, offering checking and savings accounts, internet banking, debit cards, certificates of deposit, brokerage services and others. Its primary source of revenue is net interest income derived from lending and deposit taking activities.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: